Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone862-261-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.79 billion
Profitability
Miscellaneous
Employees16,900
Next Earnings Date4/29/2019 (Estimated)
OptionableOptionable
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan announced a quarterly dividend on Friday, January 25th. Stockholders of record on Friday, February 15th will be given a dividend of $0.74 per share on Friday, March 15th. This represents a $2.96 annualized dividend and a dividend yield of 1.92%. The ex-dividend date is Thursday, February 14th. This is an increase from Allergan's previous quarterly dividend of $0.72. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan declared that its Board of Directors has approved a stock repurchase program on Tuesday, January 29th 2019, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 4.1% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its stock is undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) posted its quarterly earnings results on Tuesday, January, 29th. The company reported $4.29 EPS for the quarter, beating analysts' consensus estimates of $4.15 by $0.14. The company had revenue of $4.08 billion for the quarter, compared to analyst estimates of $4 billion. Allergan had a negative net margin of 32.28% and a positive return on equity of 8.18%. The firm's revenue was down 5.7% on a year-over-year basis. During the same period last year, the business posted $4.86 earnings per share. View Allergan's Earnings History.
When is Allergan's next earnings date?
What guidance has Allergan issued on next quarter's earnings?
Allergan issued an update on its first quarter 2019 earnings guidance on Tuesday, January, 29th. The company provided earnings per share (EPS) guidance of $3.40-3.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.75. The company issued revenue guidance of $3.4-3.55 billion, compared to the consensus revenue estimate of $3.65 billion.Allergan also updated its FY19 guidance to $16.36 EPS.
What price target have analysts set for AGN?
20 equities research analysts have issued twelve-month price objectives for Allergan's shares. Their predictions range from $155.00 to $255.00. On average, they expect Allergan's share price to reach $194.5882 in the next year. This suggests a possible upside of 26.2% from the stock's current price. View Analyst Price Targets for Allergan.
What is the consensus analysts' recommendation for Allergan?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergan.
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, Allergan faces loss of exclusivity for many key products. While generic versions of Alzheimer’s treatment, Namenda XR and Estrace cream have been launched, that of blockbuster dry-eye drug, Restasis, is expected to be launched soon. Sales of these products are expected to decline significantly with the introduction of generics. Also, new competition for key growth drivers, Botox, Restasis and Linzess, is a concern. Particularly, the entry of CGRP antibodies in 2018 may have a negative impact on sales of Botox Therapeutics, mainly for the chronic migraine indication. Allergan’s shares have underperformed the industry in the past three months." (1/3/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate AGN Neutral and have a 12-month price target of $180. We think that Allergan is one the highest-quality and most-innovative companies in the Pharma industry. That said, we don’t see a lot of upside to consensus expectations in the near term, which is why we are on the sidelines for now. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $180." (9/14/2018)
- 3. Mizuho analysts commented, "We note that Mylan has invalidated Restasis patents, and Allergan mgmt. noted that two other generic manufacturers (Teva and Akorn that have not settled) could also launch Restasis generics if their applications are FDA-approved. We know that Allergan separately entered into five other generic settlements, according to its 1Q:18 10-Q filing. No news from Mylan or the others would be good news to Allergan, in our view." (7/30/2018)
Has Allergan been receiving favorable news coverage?
Headlines about AGN stock have trended neutral recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN) and Takeda Pharmaceutical (TAK).
What other stocks do shareholders of Allergan own?
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
- Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)
Who are Allergan's major shareholders?
Allergan's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.36%), Oregon Public Employees Retirement Fund (6.16%), Longview Partners Guernsey LTD (1.79%), Baupost Group LLC MA (1.41%), FMR LLC (1.28%) and Northern Trust Corp (1.20%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz and William Meury. View Institutional Ownership Trends for Allergan.
Which major investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Parnassus Investments CA, Jennison Associates LLC, Millennium Management LLC, CIBC Private Wealth Group LLC, Baupost Group LLC MA, Orbimed Advisors LLC and Confluence Investment Management LLC. View Insider Buying and Selling for Allergan.
Which major investors are buying Allergan stock?
AGN stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Longview Partners Guernsey LTD, Norges Bank, MFN Partners Management LP, Diamond Hill Capital Management Inc., BlackRock Inc., Boston Partners and Squarepoint Ops LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $154.14.
How big of a company is Allergan?
Allergan has a market capitalization of $51.27 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.
What is Allergan's official website?
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (NYSE AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
